Library - page 13

Actual

Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"

The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemispherical ischemic stroke (the results of subanalysis of a randomized double blind multicenter placebo-controlled epic study)

Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension

Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA) Link to study status here

Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol

The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis

The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis

Arterial hypertension and cognitive disorders. The gaze of a neurologist

Reproduced drugs: Benefit ratio/risk

Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"

Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension

Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol

The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis

The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis

Arterial hypertension and cognitive disorders. The gaze of a neurologist

Reproduced drugs: Benefit ratio/risk

Features of the influence of Mexidol on the functional state of the central nervous system in patients who have suffered a stroke

Authors:
V.V. Kuznetsov, F.V. Yurchenko

Institute of Gerontology of AMNs of Ukraine, Kyiv

Clinical assessment of the drug Mexol in the treatment of severe traumatic brain injury at the stages of medical care

Author:
V.L. Dyushkevich

Voronezh State Medical Academy. N. N. Burdenko, Voronezh

The experience of using Mexidol in the treatment of a concussion of the brain and in the late recovery period after severe traumatic brain injuries on an outpatient basis

Author:
A.V. Ignatova

MBUZ City Polyclinic No. 26, Novosibirsk

Randomized dual-blind, placebo-controlled study of the effectiveness and safety of Mexidol in the complex therapy of ischemic stroke in the acute period

Author:
V.I. CKBOPTSOBA, L.V. Stakhovskaya, Y.P. Narcissas, M.K. Bodykhov, I.V. Kichuk, Yu.V. Gudkova, T.A. Soldatenkova, T.T. Kondrashova, E.V. Kalinina, M.A. Novichkova, O.B. Kerbikov

Department of Fundamental and Clinical Neurology of the Russian State Medical University, Research Institute of Cytochemistry and Molecular Pharmacology, Moscow

Mexidol in the prevention of intracranial hypertension syndrome with the consequences of closed traumatic brain injury

Authors:
B.M. Doronin, A.Yu. Poyagin, O.B. Tyshkevich, V.B. Doronin

Novosibirsk State Medical University, Novosibirsk, 2006

The possibility of using Mexidol in neuropediatrics

Authors:
N.N. Zavadenko, N.Yu. Suvorinova, A.N. Zavadenko

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA) Link to study status here

Link to the status of the study here

N.N. ZAVADENKO ¹ , N.Yu. SUVORINOVA ¹ , T.T. BATYSHEVA ² , O.V. BYKOVA ² , A.N. PLATONOVA ² , D.D. GAYNETDINOVA ³ , E.V. LEVITINA ⁴ , V.V. MASHIN ⁵ , I.N. VAKULA ⁶ , N.E. MAKSIMOVA ⁷

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² GBUZ "Scientific and practical center of children's psychoneurology of the Department of Health of Moscow", Moscow, Russia;
³ FSBEI in Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia;
⁴ FSBEI in Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia;
⁵ FSBEI in Ulyanovsk State University, Ulyanovsk, Russia;
⁶ LLC "Center for Professional Therapy", Krasnodar, Russia;

⁷FSBEI in the Tver State Medical University, Tver, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T.122, No. 4

Experience in the use of Mexidol® in children and adolescents with mental disorders

Authors:
Yu.Sh. Vasyanina

The use of Mexidol® in children's neurological practice

Authors:
G.R. Khamitova

The use of Mexidol in the correction of vegetative dizregulation syndrome as the consequences of perinatal lesions of the central nervous system

Authors:
M.A. Okuneva

The course of school adaptation in children with syndrome of attention deficiency with hyperactivity against the background of the use of Mexidol

Authors:
I.S. Potapova, N.V. Khrina, M.V. Protopopova

« 1 … 11 12 13